Investigation of the liver failure patients infected with hepatitis B virus treated with entecavir

Zhong XunHua; Yuan Jing; Yang Yan; Li Wei; Chen XiaoYing

Issue 5

May 2009

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2009 > 25(5): 331-333

PDF( 165 KB)

恩替卡韦治疗乙型肝炎肝衰竭患者临床研究

Published Date: 2009-05-20

Abstract

Abstract

Objective To observe the therapeutic effects and its safety of entecavir on the patients of liver failure with hepatitis B virus infection.Methods The treatment group (n=30) were administered 0.5mg entecavir orally once daily based upon basic supportive therapy.The survival rate, liver function, complications and serum HBVDNA viral load 1 year after treatment were observed and compared with that of the matched controls.Results The survival rate in the treatment group and control were 70.00% and 43% respectively and the survival rate of the treatment group was significantly higher than that of the controls (x2=4.34, P<0.05) .The improvement of liver function and serum HBV DNA viral load at undetectable level at 1year after therapy in enticavir treatment group was significantly higher than that of controls.Morbidity of complications in the treatment group with a good drug safety was superior to that in controls.Conclusion Entecavir showed its positive effect and safety on the improvement of the survival rate and the life quality in patients with hepatitis B liver failure.
- entecavir,
- liver failure,
- hepatitis B

FullText(HTML)

References(8)

References

[1]陈菊梅, 邹正升.重视乙型肝炎肝衰竭的预防和控制[J].传染病信息, 2008, 21 (2) :65-67.

[2]王宇明, 于乐成.乙型肝炎病毒相关肝衰竭的进展:发病机制和治疗[J].肝脏, 2008, 13 (1) :60-518.

[3]Shaw T, Locarnini S.Entecavir for the treatment of chronichepatitis B[J].Expert Rev Anti Infect Ther, 2004, 2 (6) :853-871.

[4]刘磊, 韩涛, 李莹.恩替卡韦治疗乙型肝炎肝硬化48周疗效观察[J].武警医学院学报, 2008, 17 (4) :307-309.

[5]张耀, 郑莎, 王宇明.拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].第三军医大学学报, 2008, 30 (9) :848-850.

[6]中华医学会感染病学分会肝衰竭与人工肝学组.肝衰竭诊疗指南[J].中华内科杂志, 2006, 45 (12) :1053-1056.

[7]Tenney DJ, Rose RE, Baldick CJ, et al.Two-year assessment of en-tecavir resistance in Lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substi-tutions present[J].Antimicrob Agents Chemother, 2007, 51:902-911.

[8]毛日成, 张继明, 尹有宽, 等.恩替卡韦耐药乙型肝炎病毒株的出现和消失[J].肝脏, 2007, 12 (3) :171-174.

Relative Articles

[1]	Zhang Qing, Zhang Biao, Wang Pei, Li Ying, Yan XueBing, Ding Qin. Influence of long-term entecavir treatment on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(7): 1491-1495. doi: 10.3969/j.issn.1001-5256.2020.07.010
[2]	Gao ShengLi, Zhao Gang, Xu MiQin, Shen Yan, Yu Jing, Ye Yang, He LiHua, Jin WenJuan, Sun GuiYing, Niu ZhiLin. Efficacy and safety of interferon-α given additionally or sequentially after long-term entecavir therapy in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(2): 268-271. doi: 10.3969/j.issn.1001-5256.2018.02.010
[3]	Wu YanQin, Shen LiJun, Yu JiHong, Sun YuShan. Clinical effect of entecavir in treatment of chronic hepatitis B complicated by hepatic steatosis[J]. Journal of Clinical Hepatology, 2017, 33(5): 849-852. doi: 10.3969/j.issn.1001-5256.2017.05.011
[4]	Tao JunXiu, Li XiaoDong, Cao Ting, Xiao MingZhong, Wu HuiKun, Wu Deng, Ren Meng, Wang Ting, Bai LiYing. A study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment[J]. Journal of Clinical Hepatology, 2017, 33(8): 1558-1560. doi: 10.3969/j.issn.1001-5256.2017.08.030
[5]	Ji HuiChun, Zhang ZhenJiang, Zhu Fang, Liu JunQuan, Liu QingDe, Pang Wei. Clinical effect of alprostadil combined with entecavir in treatment of HBV-related liver failure complicated by ascites[J]. Journal of Clinical Hepatology, 2016, 32(11): 2151-2154. doi: 10.3969/j.issn.1001-5256.2016.11.030
[6]	Li HuiLi, Lu XueFeng, Li Na. Efficacy of entecavir combined with alprostadil in treatment of hepatitis B-related cirrhotic ascites[J]. Journal of Clinical Hepatology, 2016, 32(2): 292-295. doi: 10.3969/j.issn.1001-5256.2016.02.019
[7]	Han BenLi. Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1525-1528. doi: 10.3969/j.issn.1001-5256.2016.08.018
[8]	Xie YongCai, Hu GuoXin, Peng YanZhong, Zheng Jie, Li YinPing. Clinical effect of Dahuang Zhechong capsules combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1502-1507. doi: 10.3969/j.issn.1001-5256.2016.08.014
[9]	Zhu DongLiang, Li DaoBo, Zhao ManZhi, Ma Ke, Song JianXin, Xu Dong. Clinical effect of entecavir in treatment of patients with chronic hepatitis B complicated by tuberculosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2084-2087. doi: 10.3969/j.issn.1001-5256.2016.11.014
[10]	Xia ShuLin, He XiaoFeng. Efficacy of entecavir treatment for patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(4): 523-525. doi: 10.3969/j.issn.1001-5256.2015.04.011
[11]	Gao YuanZheng, Jia SuHua, Zhao LianFeng, Jiang Ying, Wang Yan. Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(4): 314-316. doi: 10.3969/j.issn.1001-5256.2014.04.007
[12]	Gou Wei, Wang YanLing, Xu XiaoWei, Xu WenWei. Clinical efficacy of entecavir in treatment of hepatogenous diabetes [J]. Journal of Clinical Hepatology, 2013, 29(6): 456-458.
[13]	Zheng YuShan, Sun FengLan, Liu XianHong. Comparative study on the therapeutic effects of telbivudine and entecavir on acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2011, 27(6): 641-642+646.
[14]	Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng. Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
[15]	Chen FangZhi, Li GuoQing, Zhang Li, Liu HongYing. Clinical effect of entecavir in patients with decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2010, 26(6): 608-609+612.
[17]	Kan Xiao, Shi ZhaoZhang, Zheng ZhaoMin, Han ShaoLei. The effect of Entikawei in the treatment of hopatitis B virus associated glomerulonephritis (HBV-GN)[J]. Journal of Clinical Hepatology, 2008, 24(6): 426-427.
[18]	Luo WeiMin, Zhang YingChun, Liu ZhongJing. Clinical Observation about Entecavir in Treating Chronic Hepatitis B at the Initial Stage.[J]. Journal of Clinical Hepatology, 2008, 24(1): 26-28.
[20]	Yang GuiSheng, Wang HaiTao, Chang AiNa. Study of Entecavir in treating chronic hepatitis B Patients[J]. Journal of Clinical Hepatology, 2007, 23(6): 426-427.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2244) PDF downloads(879)

恩替卡韦治疗乙型肝炎肝衰竭患者临床研究

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

恩替卡韦治疗乙型肝炎肝衰竭患者临床研究

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content